Coca-Cola, Microsoft Forge $1.1B Alliance for Cloud and AI Innovation 
Lotte Starts Online Sales of Premium Bacha Coffee Line 
Tevfik Arif shares his take on the post-COVID-19 real estate market in New York City 
Lotte Department Store Launches AI Translation Service for Foreign Customers 
PUMA Launches Innovative Compostable Sneaker RE:SUEDE 2.0 
BYD Unwraps New Electric Pickup Truck It Named BYD Shark 
Apple Adds Eight Chinese Companies to Its Supply Chain After Axing Four 
Hollys Brews Expansion with First Overseas Outlet in Japan in May 
Rivian's Earth Day Special: $5,000 Off for Trading Gas Cars for Electric 
Adidas Unveils Groundbreaking Wheelchair Basketball Uniforms in Collaboration with Adaptive Sports Northwest 
Kroger and Albertsons Extend Store Sale to C&S by 166 Stores in Push for Merger Approval 
Amazon to Introduce Air Delivery Service in Arizona via Drone 
Tesla Expands in Thailand: New Interest Rate Program and Land Acquisition Talks 
South Korean Fashion Labels Unite to Combat Counterfeit Products 
How corporate involvement in psychedelic research could threaten public safety 
ADM’s Suspended CFO to Resign After Accounting Probe 
China's EV Price Battle Intensifies with Tesla's Strategic Cuts 
SYDNEY, Australia, March 21, 2018 -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) has announced the initiation of patient dosing in the new cohort of the TACTI-mel (Two ACTive Immunotherapies in melanoma) Phase 1 clinical trial. This clinical study is evaluating the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha (“efti” or “IMP321”) with pembrolizumab (KEYTRUDA®) in unresectable or metastatic melanoma patients in Australia.
The additional cohort consists of six patients that will receive 30 mg of efti in combination with pembrolizumab starting at cycle one of pembrolizumab. Patients will be treated for up to 12 months. Yesterday the first patient in this cohort received their first dose of the two drugs. Safety assessment is the main objective of this study.
“This additional cohort of the ongoing TACTI-mel clinicial trial is very important to the clinical development of efti, especially in the light of our new collaboration study announced on 12th of March 2018, as we are now dosing efti at cycle one in combination with KEYTRUDA® with the highest dose and for a 12-month duration,” said Dr. Frédéric Triebel, Immutep’s Chief Scientific Officer and Chief Medical Officer. “We look forward to presenting additional data from the TACTI-mel study during the middle of this calendar year as we hope it will further support our hypothesis that combining an antigen-presenting cell activator (efti) with a checkpoint inhibitor (KEYTRUDA®) results in a therapeutic synergy and a potential benefit over checkpoint inhibitor monotherapy.”
About Immutep
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the U.S.
For further information please visit www.immutep.com or contact:
U.S. Investors:
Jay Campbell, Vice President of Business Development and Investor Relations, Immutep Limited
+1 (917) 860-9404; [email protected]
Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; [email protected]
